The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
A major difference in the revised diagnostic criteria for Alzheimer's disease (AD) is the incorporation of biomarkers to support a clinical diagnosis and allow the identification of preclinical AD due to AD neuropathological processes. However, AD-specific fluid biomarkers which specifically di...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4536228?pdf=render |
id |
doaj-4712b40ebf12452fbaa2198e81414d94 |
---|---|
record_format |
Article |
spelling |
doaj-4712b40ebf12452fbaa2198e81414d942020-11-24T21:51:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013545810.1371/journal.pone.0135458The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.Malin WennströmYulia SurovaSara HallChrister NilssonLennart MinthonOskar HanssonHenrietta M NielsenA major difference in the revised diagnostic criteria for Alzheimer's disease (AD) is the incorporation of biomarkers to support a clinical diagnosis and allow the identification of preclinical AD due to AD neuropathological processes. However, AD-specific fluid biomarkers which specifically distinguish clinical AD dementia from other dementia disorders are still missing. Here we aimed to evaluate the disease-specificity of increased YKL-40 levels in cerebrospinal fluid (CSF) from AD patients with mild to moderate dementia (n = 49) versus Parkinson's disease (PD) (n = 61) and dementia with Lewy bodies (DLB) patients (n = 36), and non-demented controls (n = 44). Second we aimed to investigate whether altered YKL-40 levels are associated with CSF levels of other inflammation-associated molecules. When correcting for age, AD patients exhibited 21.3%, 27.7% and 38.8% higher YKL-40 levels compared to non-demented controls (p = 0.0283), DLB (p = 0.0027) and PD patients (p<0.0001). The AD-associated increase in YKL-40 was not associated with CSF P-tau, T-tau or Aβ42. No relationship between increased YKL-40 and levels of the astrocytic marker glial-fibrillary acidic protein (GFAP), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and interferon gamma-induced protein 10 (IP-10) could be identified. Our results confirm previous reports of an age-associated increased in CSF YKL-40 levels and further demonstrate increased CSF YKL-40 in AD patients versus non-demented controls and patients with DLB or PD. The increase in YKL-40 levels in the AD patients was unrelated to the established CSF AD biomarkers and the inflammatory markers GFAP, MCP-1, IP-10 and IL-8, proposing YKL-40 as a marker of yet to be identified AD-related pathological processes.http://europepmc.org/articles/PMC4536228?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Malin Wennström Yulia Surova Sara Hall Christer Nilsson Lennart Minthon Oskar Hansson Henrietta M Nielsen |
spellingShingle |
Malin Wennström Yulia Surova Sara Hall Christer Nilsson Lennart Minthon Oskar Hansson Henrietta M Nielsen The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. PLoS ONE |
author_facet |
Malin Wennström Yulia Surova Sara Hall Christer Nilsson Lennart Minthon Oskar Hansson Henrietta M Nielsen |
author_sort |
Malin Wennström |
title |
The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. |
title_short |
The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. |
title_full |
The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. |
title_fullStr |
The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. |
title_full_unstemmed |
The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. |
title_sort |
inflammatory marker ykl-40 is elevated in cerebrospinal fluid from patients with alzheimer's but not parkinson's disease or dementia with lewy bodies. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
A major difference in the revised diagnostic criteria for Alzheimer's disease (AD) is the incorporation of biomarkers to support a clinical diagnosis and allow the identification of preclinical AD due to AD neuropathological processes. However, AD-specific fluid biomarkers which specifically distinguish clinical AD dementia from other dementia disorders are still missing. Here we aimed to evaluate the disease-specificity of increased YKL-40 levels in cerebrospinal fluid (CSF) from AD patients with mild to moderate dementia (n = 49) versus Parkinson's disease (PD) (n = 61) and dementia with Lewy bodies (DLB) patients (n = 36), and non-demented controls (n = 44). Second we aimed to investigate whether altered YKL-40 levels are associated with CSF levels of other inflammation-associated molecules. When correcting for age, AD patients exhibited 21.3%, 27.7% and 38.8% higher YKL-40 levels compared to non-demented controls (p = 0.0283), DLB (p = 0.0027) and PD patients (p<0.0001). The AD-associated increase in YKL-40 was not associated with CSF P-tau, T-tau or Aβ42. No relationship between increased YKL-40 and levels of the astrocytic marker glial-fibrillary acidic protein (GFAP), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and interferon gamma-induced protein 10 (IP-10) could be identified. Our results confirm previous reports of an age-associated increased in CSF YKL-40 levels and further demonstrate increased CSF YKL-40 in AD patients versus non-demented controls and patients with DLB or PD. The increase in YKL-40 levels in the AD patients was unrelated to the established CSF AD biomarkers and the inflammatory markers GFAP, MCP-1, IP-10 and IL-8, proposing YKL-40 as a marker of yet to be identified AD-related pathological processes. |
url |
http://europepmc.org/articles/PMC4536228?pdf=render |
work_keys_str_mv |
AT malinwennstrom theinflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT yuliasurova theinflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT sarahall theinflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT christernilsson theinflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT lennartminthon theinflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT oskarhansson theinflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT henriettamnielsen theinflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT malinwennstrom inflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT yuliasurova inflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT sarahall inflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT christernilsson inflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT lennartminthon inflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT oskarhansson inflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies AT henriettamnielsen inflammatorymarkerykl40iselevatedincerebrospinalfluidfrompatientswithalzheimersbutnotparkinsonsdiseaseordementiawithlewybodies |
_version_ |
1725880262422691840 |